Reviews/Dietary Fibre/Fibre lowers C-reactive protein
Systemic · FIBRE-SYS-03 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
Many studies in this corpus look at whether people who eat more fibre have lower levels of inflammation markers in their blood, such as C-reactive protein. In large population surveys and other observational datasets, higher fibre intake goes hand in hand with lower inflammation markers [22][26][28][29]. A few controlled trials also found genuine drops, in one case in an inflammatory protein called TNF-alpha [3] and in another in C-reactive protein [7]. But several of the better-controlled trials found little or no change [1][15][16], the effects seen are modest, and the fibre was often changed alongside other parts of the diet. The panel judged the direction of the effect to be well supported but not firmly settled, which is why it landed between the strong observational signal and the weaker trial evidence.
Six independent human observational datasets link higher fibre intake to lower circulating inflammation markers: NHANES cross-sectional data [22][26][29], a case-control study where fibre was inversely correlated with CRP (r=-0.52) and IL-6 (r=-0.48) [28], a cross-sectional study [25], and a prospective cohort [23]. Two randomised trials found significant reductions, in plasma TNF-alpha [3] and in CRP between diets (P=0.017) [7]. The direction of effect is consistent across varied populations including metabolic syndrome [22], Crohn's disease risk [23] and COPD [28]. A plausible mechanism through short-chain fatty acids is described in several papers [2][19]. The contested point: The division is between the observational data, which is consistent but cannot rule out healthy-user and reverse-causation confounding, and the randomised evidence, which is mixed: inulin had no impact on systemic markers [1], hs-CRP was non-significant in hemodialysis patients [15], and only trended (p=0.063) in type 2 diabetes [16]. Even the formal mediation in [22] attributes only 7.4% of the fibre effect on metabolic syndrome to lower CRP.
All 29 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Dietary Fibre, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The randomised evidence best able to establish causation is inconsistent: inulin had no impact on systemic markers [1], hs-CRP was non-significant in hemodialysis patients [15], and only trended (p=0.063) in type 2 diabetes [16]. Several of the clearest reductions come only from observational data.
The strongest and most consistent signal is observational [22][25][26][28][29], which cannot exclude healthy-user and reverse-causation confounding; even the formal mediation in [22] attributes only 7.4% of the fibre-metabolic effect to CRP.
Where it remains uncertain. The clearest reductions come from observational data vulnerable to confounding [22][25][26][28][29], while the trials best able to show causation were null or near-null [1][15][16].
Aleatory
Intervention trials are small ([1] n=12, [7] n=25, [16] n=28), so chance variation can obscure or exaggerate modest effects.
Epistemic
Controlled trials disagree: significant falls in [3][7] against null [1][15] and a p=0.063 trend [16], leaving the true controlled effect unresolved.
Inferential
The strongest signal [22][25][26][28][29] is cross-sectional or case-control and cannot exclude healthy-user or reverse-causation confounding.
The load-bearing papers from a corpus of 29, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Shows the effect is fibre-type dependent; inulin alone produced no systemic anti-inflammatory signal
“IPE supplementation decreased proinflammatory interleukin-8 levels compared with cellulose, while inulin had no impact on the systemic inflammatory markers studied.”
Panel auditInternal validity: medium · scope of inference: Non-diabetic overweight/obese adults; colonic propionate delivery via engineered ester vs fermentable and non-fermentable fibre.Key limitations: very small n · split result across fibre types · no p value for inflammation endpoint
RCT showing whole-grain/fibre intake lowers a systemic pro-inflammatory cytokine
“Concomitant reduction in plasma tumor necrosis factor-α (TNF-α) after 8 wk and increased interleukin (IL)-10 only after 4 wk with WG compared with RW (P = 0.04) were observed.”
Panel auditInternal validity: medium · scope of inference: Overweight/obese subjects with poor baseline diet; whole-grain wheat as fibre-plus-polyphenol source.Key limitations: fibre effect confounded with polyphenols · timing-dependent effects
RCT causal evidence that a high-fibre diet lowers CRP, a systemic inflammatory marker
“Significant reduction in C-reactive protein (CRP) was observed between the diets (P = 0.017) and a significant reduction in fibrinogen within the HF diet (P = 0.044).”
Panel auditInternal validity: medium · scope of inference: Middle-aged mildly hypercholesterolaemic adults; mixed cereal/beet fibre.Key limitations: small n · CRP lowered but other cytokines unchanged
Interventional reduction in a systemic acute-phase marker, but fat and fibre co-varied
“Serum amyloid A decreased significantly from 7.99 mg/L at baseline to 4.50 mg/L after LFD (P = .02)”
Panel auditInternal validity: low · scope of inference: UC patients in remission/mild disease; combined low-fat high-fibre dietary intervention.Key limitations: combined intervention cannot isolate fibre · small n · not significant vs active comparator
4 of 29 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The consistent direction across many human studies and a plausible SCFA mechanism support a modest lowering effect, but mixed RCT results and surrogate biomarker endpoints keep it short of Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Adequately powered fibre-isolated RCT. The trials best able to show causation are small or null, so the causal claim rests largely on observational data. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised controlled trial supplementing a single fibre at a fixed dose against an inert control, powered on CRP or IL-6 as the primary endpoint in a general adult population.
Open question: Does supplementing fibre alone, without other dietary changes, significantly lower systemic inflammatory markers in a general adult population? Why it is still open: The cleaner randomised trials were null or only trended [1][15][16], while positive trials bundled fibre with other changes [3][4].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19